• Vaccine Ontology ID: VO_0004370
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse, guinea pig
• Antigen: gD and gB from HSV-2 strain Curtis (McClements et al., 1997)
• gD gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector V1Jns expressed HSV envelope glycoproteins D (gD) (McClements et al., 1997).
  • Detailed Gene Information: Click Here.
• UL27 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector V1Jns expressed HSV envelope glycoprotein B (UL27) (McClements et al., 1997).
  • Detailed Gene Information: Click Here.
• Vector: V1Jns (McClements et al., 1997)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004710
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• gD gene engineering:
  • Type: Recombinant vector construction
  • Description: The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
  • Detailed Gene Information: Click Here.
• Preparation: Herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
• Immunization Route: Intramuscular injection (i.m.)

Guinea pig Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: Immunization with a plasmid expressing gB induced humoral immune responses and virus neutralization (McClements et al., 1997).
• Efficacy: When the gB plasmid was combined with a plasmid expressing full-length gD, immunized guinea pigs developed humoral responses to both proteins and were also significantly protected from viral challenge. In addition, immunized animals were partially protected from genital herpes, exhibiting significantly reduced primary and subsequent recurrent disease (McClements et al., 1997).

Guinea pig Response

• Vaccination Protocol: The guinea pigs were inoculated with three doses of uninfected human fibroblasts, fibroblasts infected with ROka VZV, or fibroblasts infected with ROka-gD2 (Heineman et al., 1995).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: The guinea pigs were challenged intravaginally with HSV-2 (Heineman et al., 1995).
• Efficacy: Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001). These experiments demonstrate that the Oka strain of VZV can be used as a live virus vector to protect animals from disease with a heterologous virus (Heineman et al., 1995).